Open AccessToward the development of true “off‐the‐shelf” synthetic T‐cell immunotherapy
Author(s) -
Iriguchi Shoichi,
Kaneko Shin
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13892
Subject(s) - induced pluripotent stem cell , chimeric antigen receptor , off the shelf , immunotherapy , cell therapy , adoptive cell transfer , microbiology and biotechnology , biology , stem cell , cell , immunology , t cell , computational biology , computer science , immune system , embryonic stem cell , genetics , software engineering , gene
Recent outstanding clinical results produced by engineered T cells, including chimeric antigen receptors, have already facilitated further research that broadens their applicability. One such direction is to explore new T cell sources for allogeneic “off‐the‐shelf” adoptive immunotherapy. Human pluripotent stem cells could serve as an alternative cell source for this purpose due to their unique features of infinite propagation ability and pluripotency. Here, we describe the current state of engineered T cell transfer with the focus on cell manufacturing processes and the potentials and challenges of induced pluripotent stem cell‐derived T cells as a starting material to construct off‐the‐shelf T‐cell banks.